Form Approved OMB No. 0920-0666 Exp. Date: xx/xx/20xx

www.cdc.gov/nhsn



CDC 57.304 Rev. 4, v8.0

## Hemovigilance Module Adverse Reaction

*Required for saving  *Facility ID#:	NHSN Adverse R	Reaction #:			
Patient Information	111101111111111111111111111111111111111				
T dations information					
*Patient ID: *Gende	er: M F Other	*Date of Birth:///			
Social Security #: Secon	dary ID:	Medicare #:			
Last Name: First Na	ame:	Middle Name:			
Ethnicity Hispanic or Latino Not F	lispanic or Not Latino				
American Indian/Alaska	Asian Black or Afr	ican American			
Race Native Native Hawaiian/Other Pacific		ican American			
Native Hawaiian/Other Pacific	, islatiuei writte				
*Blood Group: A- A+ B- +	AB- AB+ O- O				
*Primary underlying reason for transfusion:	Congularathy	Hematology etic Disorder Disorder			
Hemolysis Internal Bleeding	Malignancy Medi				
Other (specify)	_ , _				
Reaction Details					
*Date reaction occurred://					
*Time reaction occurred: : (HH:MM					
*Facility location where patient was transfused	· —				
*Is this reaction associated with an incident?		s, Incident #:			
		s, incluent #			
*Signs and symptoms, laboratory: (check all the Cardiovascular:	Cutaneous:	Pain:			
Blood pressure decrease	Edema	Abdominal pain			
Shock	Flushing	Back pain			
Hemolysis/Hemorrhage	Jaundice	Flank pain			
Disseminated intravascular coagulation	Other rash	Infusion site pain			
Hemoglobinemia	Pruritus (itching)	Respiratory:			
Positive antibody screen	Urticaria (hives)	Bilateral infiltrates on chest x-ray			
Generalized:	Renal:	Bronchospasm			
Chills/rigors	Hematuria	Cough			
Fever	Hemoglobinuria	Hypoxemia			
Nausea/vomiting	Oliguria	Shortness of breath			
U Other: (specify)					
Assurance of Confidentiality: The voluntarily provided information obtained in this surveillance system that would permit identification of any individual or institution is collected with a guarantee that it will be held in strict confidence, will be used only for the purposes stated, and will not					
otherwise be disclosed or released without the consent of the individual, or the institution in accordance with Sections 304, 306 and 308(d) of the Public Health Service Act (42 USC 242b, 242k, and 242m(d)).					
Public reporting burden of this collection of information is estimated to average 15 minutes per response, including the time for reviewing instructions,					

Form Approved OMB No. 0920-0666 Exp. Date: xx/xx/20xx



www.cdc.gov/nhsn

searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. An agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to CDC, Reports Clearance Officer, 1600 Clifton Rd., MS D-74, Atlanta, GA 30333 ATTN: PRA (0920-0666).

Investigation Results (Use ca	ase defini	tion criteria i	n protocol.)			
*Adverse reaction: (check one)						
Allergic reaction, including	anaphyla	xis				
Acute hemolytic transfusion	reaction	(AHTR)				
Immune Antibody: Non-immune (specify)						
Delayed hemolytic transfus	ion reacti	on (DHTR)				
Immune Antibody:			Non-immune (spe	cify)		
Delayed serologic transfusi	on reaction		A 4:1			
(DSTR)	fucion ro					
Febrile non-hemolytic trans  Hypotensive transfusion rea		action (FINH)	ik)			
Infection	action					
Was a test to detect a speci	fic nathon	en nerformed	I on the recinient no	st-transfusion?		
		e or reactive r				
Org1	•					
Was a test to detect a specif						
	-	e or reactive r				
Org1	· -					
Was a test to detect a specif		•				
	-	e or reactive r				
Org1	Org1 Org2 Org3					
Post transfusion purpura (F						
Transfusion associated circ	culatory o	verload (TAC	CO)			
Transfusion associated dys	pnea (TA	AD)				
Transfusion associated gra	ft vs. hos	t disease (TA	A-GVHD)			
Did patient receive non-irrac	liated bloo	nd product(s)	in the two months n	receding the reaction	n? Yes No	
Transfusion related acute la			in the two months p	receaming the reaction	11. 105	
Antibody studies performed:		•				
			Test result positiv	e		
			Cognate or	No cognate or	Not tested for	
	Not Done	Mogativo	cross reacting antigen present	cross reacting antigen present	cognate	
Danar ar unit III A anacificity	Done	Negative	antigen present	antigen present	antigen	
Donor or unit HLA specificity						
Donor or unit HNA specificity						
Recipient HLA specificity						
Recipient HNA specificity						
Unknown						
Other (specify)						

Form Approved OMB No. 0920-0666 Exp. Date: xx/xx/20xx

N-SN National Healthcare

National Healthcare Safety Network					W	vw.cdc.gov/nhsn
*Case definition	criteria: Defini	tive	Probable	Possible	N/A	
*Severity: N	Ion-severe Se	vere [	Life-threatenir	g Death	Not determined	
*Imputability:	Definite Pro	bable	Possible	Doubtful	Ruled Out Not do	etermined
Outcome						
*Outcome:	Death⁺	or long	-term sequelae	Minor or no	sequelae Not	determined
Date of Death:			<sup>†</sup> Deaths attribut	able to transfus	sion must be reporte	d to FDA.
^If recipient die	d, relationship of tra	ansfusio	on to death:			
Definite	Probable	Possib	le Doubtful	Ruled Out	Not determined	d
Component De	etails (Use workshe	et on pa	age 4 for addition	al units.)		
*Was a particula	r unit implicated in (	i.e., res	<i>'</i>	adverse reaction	n? Yes No	
	*Component code		^Unit number Required for			Implicated in the
*Transfusion <b>End</b>	(check system	*# of	TRALI, GVHD,	*Unit expiration		adverse
Date/Time	used)	units	Infection	Date/Time	*Blood group of unit	reaction?
^IMPLICATED UN	JIT					
	ISBT-128					
	Codabar	1			A- A+ B-	V
		1			B+ AB- AB+	Y
					O- O+ N/A	
·	ISBT-128			-	0 0 10/1	
, ,					A- A+ B-	
//	Codabar					N
					B+ AB- AB+	
:				:	O- O+ N/A	
	ISBT-128					
	Codabar				A- A+ B-	N
					B+ AB- AB+	'
:				:	O- O+ N/A	
<b>Custom Fields</b>						
Label			Labe	 el		
	1	1			1 1	
-	<del></del>					
Comments						

Form Approved OMB No. 0920-0666 Exp. Date: xx/xx/20xx

www.cdc.gov/nhsn

Nμ	<del>M</del>
National Safety	Healthcare Network

Component Details (continued)						
*Transfusion <b>End</b> Date/Time	*Component code (check system used)	*# of units	^Unit number Required for TRALI, GVHD, Infection	*Unit expiration Date/Time	*Blood group of unit	Implicated in the adverse reaction?
	ISBT-128 Codabar				A- A+ B- B+ AB- AB+ O- O+ N/A	N
	ISBT-128 Codabar				A- A+ B- B+ AB- AB+ O- O+ N/A	N
	ISBT-128 Codabar				A- A+ B- B+ AB- AB+ O- O+ N/A	N
	ISBT-128 Codabar			<i>J J</i>	A- A+ B- B+ AB- AB+ O- O+ N/A	N
	ISBT-128 Codabar				A- A+ B- B+ AB- AB+ O- O+ N/A	N
	ISBT-128 Codabar				A- A+ B- B+ AB- AB+ O- O+ N/A	N
	ISBT-128 Codabar				A- A+ B- B+ AB- AB+ O- O+ N/A	N